Eagle Pharmaceuticals, Inc. (EGRX)
After hours:
- GlobeNewswire
Eagle Pharmaceuticals Provides Business Update and Guidance for 2023
WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from 2021.1Eagle exited 2022 with an approximate 6%2 share of the commercial s
- Zacks
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- GlobeNewswire
Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference as follows: Date:Tuesday, January 10, 2023Time:10:30AM PT/1:30PM ETWebcast:Click Here The webcast of the presentation will be accessible for 30 days thereafter, via the Company’s website at www.eagleus.co
